valproic acid has been researched along with Panic Disorder in 17 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A number of preclinical studies and preliminary clinical reports, in some cases augmented by controlled studies, suggest that valproate and carbamazepine may have therapeutic effects in the treatment of certain anxiety disorders (panic disorder, post-traumatic stress disorder), alcohol and sedative-hypnotic withdrawal states, and behavioral dyscontrol syndromes." | 8.78 | Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. ( Friedman, LM; Keck, PE; McElroy, SL, 1992) |
| "Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments." | 7.68 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| "These findings suggest that valproic acid may be effective for the treatment of panic disorder." | 5.07 | Panic disorder: treatment with valproate. ( Noyes, R; Woodman, CL, 1994) |
| "Evidence from preclinical studies, preliminary clinical reports, pharmacologic challenge studies and a small number of controlled trials suggests that several antiepileptic agents--valproate, carbamazepine, and clonazepam--may have therapeutic effects in the treatment of patients with panic disorder." | 4.78 | Antiepileptic drugs for the treatment of panic disorder. ( Bennett, JA; Keck, PE; McElroy, SL; Smith, JM; Tugrul, KC, 1993) |
| "A number of preclinical studies and preliminary clinical reports, in some cases augmented by controlled studies, suggest that valproate and carbamazepine may have therapeutic effects in the treatment of certain anxiety disorders (panic disorder, post-traumatic stress disorder), alcohol and sedative-hypnotic withdrawal states, and behavioral dyscontrol syndromes." | 4.78 | Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. ( Friedman, LM; Keck, PE; McElroy, SL, 1992) |
| "Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments." | 3.68 | Sodium valproate and clonazepam for treatment-resistant panic disorder. ( Fontaine, R; Ontiveros, A, 1992) |
| "Substance abuse is a common comorbid illness in patients with mood disorders." | 2.69 | Divalproex sodium in substance abusers with mood disorder. ( Albanese, MJ; Clodfelter, RC; Khantzian, EJ, 2000) |
| " Mean dosage was 687 (SD = 234) mg/day (min 400, max 1,500 mg/day)." | 1.36 | Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study. ( Akiskal, HS; Frare, F; Perugi, G; Toni, C; Tusini, G; Vannucchi, G, 2010) |
| " Adverse effects include sedation, dyspepsia and headache early in treatment, and sexual dysfunction and increased anxiety, but these can be effectively managed with proper dosage escalation and management." | 1.30 | A risk-benefit assessment of pharmacological treatments for panic disorder. ( Bennett, JA; Dwight, M; Keck, PE; Moioffer, M; Stanton, SP, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (64.71) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Esposito, M | 1 |
| Giunta, A | 1 |
| Del Duca, E | 1 |
| Manfreda, V | 1 |
| Troisi, A | 1 |
| Bianchi, L | 1 |
| Fargnoli, MC | 1 |
| Lambru, G | 1 |
| Castellini, P | 1 |
| Bini, A | 1 |
| Evangelista, A | 1 |
| Manzoni, GC | 1 |
| Torelli, P | 1 |
| Perugi, G | 1 |
| Frare, F | 1 |
| Toni, C | 1 |
| Tusini, G | 1 |
| Vannucchi, G | 1 |
| Akiskal, HS | 1 |
| Sheehan, DV | 1 |
| Harnett-Sheehan, K | 1 |
| Hidalgo, RB | 1 |
| Janavs, J | 1 |
| McElroy, SL | 5 |
| Amado, D | 1 |
| Suppes, T | 1 |
| Dunner, DL | 1 |
| Woodman, CL | 1 |
| Noyes, R | 1 |
| Roberts, JM | 1 |
| Malcolm, R | 1 |
| Santos, AB | 1 |
| Brady, KT | 1 |
| Sonne, S | 1 |
| Lydiard, RB | 1 |
| Keck, PE | 5 |
| Tugrul, KC | 2 |
| Bennett, JA | 3 |
| Smith, JM | 1 |
| Taylor, VE | 1 |
| Marazziti, D | 1 |
| Cassano, GB | 1 |
| Baetz, M | 1 |
| Bowen, RC | 1 |
| Moioffer, M | 1 |
| Stanton, SP | 1 |
| Dwight, M | 1 |
| Albanese, MJ | 1 |
| Clodfelter, RC | 1 |
| Khantzian, EJ | 1 |
| Friedman, LM | 1 |
| Ontiveros, A | 1 |
| Fontaine, R | 1 |
| Lawrence, JM | 1 |
2 reviews available for valproic acid and Panic Disorder
| Article | Year |
|---|---|
Antiepileptic drugs for the treatment of panic disorder.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Humans; Panic Disorder; Valproic Acid | 1993 |
Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes.
Topics: Carbamazepine; Humans; Mental Disorders; Panic Disorder; Stress Disorders, Post-Traumatic; Substance | 1992 |
3 trials available for valproic acid and Panic Disorder
| Article | Year |
|---|---|
Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Dibenzothiazepines; Doub | 2013 |
Panic disorder: treatment with valproate.
Topics: Adult; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Panic Disorder; Person | 1994 |
Divalproex sodium in substance abusers with mood disorder.
Topics: Adult; Anticonvulsants; Behavior, Addictive; Bipolar Disorder; Comorbidity; Depressive Disorder; Dru | 2000 |
12 other studies available for valproic acid and Panic Disorder
| Article | Year |
|---|---|
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series.
Topics: Adult; Agoraphobia; Antibodies, Monoclonal, Humanized; Antidepressive Agents; Antimanic Agents; Benz | 2020 |
Hemicrania continua evolving from cluster headache responsive to valproic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Depression; Dyspepsia; Female; GABA Agents; Gastritis; Head | 2008 |
Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Comorbidity; Female; Humans; Longi | 2010 |
Interactive case conference. First episode: depression and panic disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Citalopram; Clonazepam; Depression; | 2005 |
Treatment of panic disorder and comorbid substance abuse with divalproex sodium.
Topics: Adult; Alprazolam; Comorbidity; Humans; Male; Panic Disorder; Substance-Related Disorders; Treatment | 1994 |
Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients.
Topics: Adult; Alcoholism; Bipolar Disorder; Comorbidity; Depressive Disorder; Dose-Response Relationship, D | 1994 |
Valproate treatment of panic disorder and lactate-induced panic attacks.
Topics: Adult; Arousal; Female; Humans; Lactates; Lactic Acid; Male; Panic; Panic Disorder; Personality Inve | 1993 |
Valproic acid for panic disorder associated with multiple sclerosis.
Topics: Adult; Female; Humans; Multiple Sclerosis; Panic Disorder; Treatment Outcome; Valproic Acid | 1996 |
Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.
Topics: Adolescent; Adult; Affect; Aged; Agoraphobia; Anxiety Disorders; Bipolar Disorder; Cognitive Behavio | 1998 |
A risk-benefit assessment of pharmacological treatments for panic disorder.
Topics: Antidepressive Agents, Tricyclic; Benzodiazepines; Humans; Monoamine Oxidase Inhibitors; Panic Disor | 1998 |
Sodium valproate and clonazepam for treatment-resistant panic disorder.
Topics: Adult; Agoraphobia; Clonazepam; Drug Synergism; Drug Therapy, Combination; Female; gamma-Aminobutyri | 1992 |
Treatment of panic disorder and benzodiazepine withdrawal with valproate.
Topics: Adult; Agoraphobia; Clonazepam; Diazepam; Dose-Response Relationship, Drug; Humans; Male; Panic Diso | 1991 |